Siyoung A. Lim
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Siyoung A. Lim has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Alysia Cox
Department of Biomedical Engineering, University of Southern California, Los Angeles, CA, USA
2 shared publications - Eun Ji Chung
Alfred E. Mann Department of Biomedical Engineering, University of Southern California, Los Angeles, California 90089, USA
2 shared publications - Junghee Kim
Department of Biochemistry and Molecular Biology, College of Medicine, Korea University, Seoul 02841, Korea
1 shared publication - Jungwon Kim
Department of Biochemistry and Molecular Biology, College of Medicine, Korea University, Seoul 02841, Korea
1 shared publication - Kyung-Mi Lee
Korea University College of Medicine
1 shared publication - Madelynn Tung
Department of Biomedical Engineering, University of Southern California, Los Angeles, CA, USA
1 shared publication
Latest Publications
- 1 February 2022
- Published by Elsevier in Molecular Aspects of Medicine
- Vol. 83, 100991
Strategies to deliver RNA by nanoparticles for therapeutic potential
- 1 February 2022
- Published by Elsevier in Molecular Aspects of Medicine
- Vol. 83, 100991
Strategies to deliver RNA by nanoparticles for therapeutic potential
- Open Access
- 22 October 2021
- Published by KEAI Publishing in Bioactive Materials
- Vol. 12, 203-213
Clinical progress of nanomedicine-based RNA therapies
The clinical application of nanoparticles (NPs) to deliver RNA for therapy has progressed rapidly since the FDA approval of Onpattro® in 2018 for the treatment of polyneuropathy associated with hereditary transthyretin amyloidosis. The emergency use authorization or approval and widespread global use of two mRNA-NP based vaccines developed by Moderna Therapeutics Inc. and Pfizer-BioNTech in 2021 has highlighted the translatability of NP technology for RNA delivery. Furthermore, in clinical trials, a wide variety of NP formulations have been found to extend the half-life of RNA molecules such as microRNA, small interfering RNA, and messenger RNA, with limited safety issues. In this review, we discuss the NP formulations that are already used in the clinic to deliver therapeutic RNA and highlight examples of RNA-NPs which are currently under evaluation for human use. We also detail NP formulations that failed to progress through clinical trials, in hopes of guiding future successful translation of nanomedicine-based RNA therapeutics into the clinic.
- 22 October 2021
- Published by KEAI Publishing in Bioactive Materials
- Vol. 12, 203-213
Open AccessClinical progress of nanomedicine-based RNA therapies
The clinical application of nanoparticles (NPs) to deliver RNA for therapy has progressed rapidly since the FDA approval of Onpattro® in 2018 for the treatment of polyneuropathy associated with hereditary transthyretin amyloidosis. The emergency use authorization or approval and widespread global use of two mRNA-NP based vaccines developed by Moderna Therapeutics Inc. and Pfizer-BioNTech in 2021 has highlighted the translatability of NP technology for RNA delivery. Furthermore, in clinical trials, a wide variety of NP formulations have been found to extend the half-life of RNA molecules such as microRNA, small interfering RNA, and messenger RNA, with limited safety issues. In this review, we discuss the NP formulations that are already used in the clinic to deliver therapeutic RNA and highlight examples of RNA-NPs which are currently under evaluation for human use. We also detail NP formulations that failed to progress through clinical trials, in hopes of guiding future successful translation of nanomedicine-based RNA therapeutics into the clinic.
- Open Access
- 1 January 2020
- Published by XMLink in Immune Network
- Vol. 20 (2) , e14
NK Cell-Based Immunotherapies in Cancer
Shin MH, et al. Immune Netw. 2020 Mar;20(2):e14. https://doi.org/10.4110/in.2020.20.e14
- 1 January 2020
- Published by XMLink in Immune Network
- Vol. 20 (2) , e14
Open AccessNK Cell-Based Immunotherapies in Cancer
Shin MH, et al. Immune Netw. 2020 Mar;20(2):e14. https://doi.org/10.4110/in.2020.20.e14